Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.01 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced, including oligodendrocytes; strongest in retinal bipolar cells | 0.75 |
| chemistry Open Targets | reachable by antibody | 0.45 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 3 Parkinson's papers of 60 | 0.82 |
| pathways Reactome | in no curated pathway | 0.00 |
No case: the score is under the bar. Receipt 8884
Sealed predictions
- SERPINI1 in oligodendrocytes, braak+0.37 (p 0.323) → -0.09 (p 0.822)receipt 8890
- SERPINI1 in dopamine neurons, braak+0.40 (p 0.285) → +0.29 (p 0.456)receipt 8891
Swarm cases
receipt 8891: SERPINI1 in dopamine neurons, braak
- power
- full sample +0.37 (p 0.132, n 18), 95% CI -0.12 to +0.71. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.37 (p 0.132, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.35 (p 0.153, n 18). could be the mix.
- skeptic
- leave-one-out range +0.29 to +0.53, sign flips 0; without severely affected donors +0.37 (p 0.132, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for SERPINI1 in dopamine neurons.
case closed: nothing better to follow up.
receipt 8890: SERPINI1 in oligodendrocytes, braak
- power
- full sample +0.30 (p 0.225, n 18), 95% CI -0.19 to +0.67. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.34 (p 0.173, n 18). does not hold up.
- composition
- oligodendrocytes share of nuclei vs axis +0.03 (p 0.915); controlling for it: +0.50 (p 0.034, n 18). not the mix.
- skeptic
- leave-one-out range +0.21 to +0.45, sign flips 0; without severely affected donors +0.30 (p 0.225, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for SERPINI1 in oligodendrocytes.
case closed: nothing better to follow up.
Receipts
loading the receipts